The ongoing lack of diversity in clinical trials will further exacerbate health disparities in the US unless the biomedical research enterprise makes systemic changes, a National Academies report released Tuesday found.
The report calls for changes in several health agencies to require that diversity considerations have more weight in the review of new drug and research grant applications. One of those recommendations for the Food and Drug Administration will be part of a House Energy and Commerce markup Wednesday.
The recommendations mark the latest effort to tackle a challenge that the biomedical ecosystem has faced for decades. Laws and federal ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.